Is BGM0504 legal in Canada?

A tirzepatide-derived dual agonist that beat semaglutide 1 mg on glycated haemoglobin and weight in a 64 person phase 2. Its phase 3 obesity result, widely quoted at 19.3 percent weight loss, exists only as a company press release and has not been published.

BGM0504 comes from BrightGene Bio-Medical in Suzhou and is explicitly derived from tirzepatide. The published design paper says so: molecular dynamics simulations identified a salt bridge between the parent peptide and both receptors, the acylation side chain was repositioned on that basis, and the resulting molecule showed two to three times the agonist activity of tirzepatide in vitro while keeping a long plasma half-life.

Mechanism: A dual agonist at the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide receptor, the same receptor pair tirzepatide acts on, engineered from the tirzepatide scaffold. The published optimisation work used molecular dynamics simulation to identify a salt bridge between the parent peptide and both receptors at residue K20 that was not visible in the cryo-electron microscopy structures, then repositioned the fatty acid acylation side chain to preserve it.

Regulatory history: Not approved anywhere. Multiple phase 3 trials are recruiting in China and Indonesia, and a tablet formulation is in phase 1. The phase 3 obesity result announced in May 2026 has not been published in a peer-reviewed journal as of this review.

Authorises drugs for sale through a Notice of Compliance and Drug Identification Number. A compound that is not authorised for sale cannot lawfully be sold for human use, and personal importation of prescription drugs is limited.

The classification above is the The Longevity Archive reading of Health Canada, Health Products and Food Branch listings for BGM0504 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.